FierceBiotechOriginal article
{"a":[{"_":"Double shot of Vistagen’s anxiety nasal spray can’t beat placebo in ph. 2 trial","$":{"href":"/biotech/double-shot-vistagens-anxiety-nasal-spray-cant-beat-placebo-ph-2-trial","hreflang":"en"}}]}
Phase 2negativeanxiety nasal sprayNegative
AI Analysis
Summary
Vistagen's nasal spray for social anxiety failed to demonstrate efficacy over placebo in a Phase 2 trial, even at double dose. The company is exploring a subpopulation strategy as a potential path forward for FDA approval.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Failed to beat placebo in Phase 2 trial, including double dose assessment
Importance:6/10
Sentiment:
-0.85
clinical trial failurePhase 2 datasocial anxietynasal sprayplacebo comparison
Related Companies
Read the original article
Published by FierceBiotech on August 6, 2026 10:34 AM